Poliovirus vaccine options
- PMID: 9917578
Poliovirus vaccine options
Abstract
As a result of the success of immunization, indigenous wild poliomyelitis has disappeared from the United States. Of 142 confirmed cases of paralytic poliomyelitis reported in the United States from 1980 to 1996, 134 were classified as vaccine-associated paralytic poliomyelitis (VAPP). Persons with VAPP have a disabling illness, and this has caught the attention of the lay media. The risk of VAPP is one case per 750,000 doses distributed for the first dose of oral poliovirus vaccine (OPV) and one case per 2.4 million doses of OPV distributed overall. Because of this risk, most parents prefer a vaccine schedule that starts with inactivated poliovirus vaccine (IPV), even though extra injections are required. IPV does not cause VAPP. New studies show that high immunization rates can be achieved in disadvantaged populations with a schedule starting with IPV. The American Academy of Family Physicians now recommends that the first two doses of poliovirus vaccine should be IPV; that is, either an all-IPV schedule or a sequential schedule of two doses of IPV followed by two doses of OPV. OPV is no longer recommended for the first two doses and is acceptable only under special circumstances, such as when parents do not accept the recommended number of injections.
Similar articles
-
Paralytic poliomyelitis--United States, 1980-1994.MMWR Morb Mortal Wkly Rep. 1997 Jan 31;46(4):79-83. MMWR Morb Mortal Wkly Rep. 1997. PMID: 9048844
-
Vaccine policy changes and epidemiology of poliomyelitis in the United States.JAMA. 2004 Oct 13;292(14):1696-701. doi: 10.1001/jama.292.14.1696. JAMA. 2004. PMID: 15479934
-
Impact of the sequential IPV/OPV schedule on vaccination coverage levels--United States, 1997.MMWR Morb Mortal Wkly Rep. 1998 Dec 4;47(47):1017-9. MMWR Morb Mortal Wkly Rep. 1998. PMID: 9853937
-
Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.Pediatr Clin North Am. 2000 Apr;47(2):287-308. doi: 10.1016/s0031-3955(05)70208-x. Pediatr Clin North Am. 2000. PMID: 10761505 Review.
-
World wide experience with inactivated poliovirus vaccine.Vaccine. 2008 Sep 15;26(39):4978-83. doi: 10.1016/j.vaccine.2008.07.026. Epub 2008 Aug 3. Vaccine. 2008. PMID: 18680777 Review.
Cited by
-
Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment.Biometrics. 2008 Dec;64(4):1070-9. doi: 10.1111/j.1541-0420.2008.01012.x. Epub 2008 Mar 19. Biometrics. 2008. PMID: 18355384 Free PMC article.
-
Pathogenic epitopes, heterologous immunity and vaccine design.Nat Rev Microbiol. 2007 Jul;5(7):555-63. doi: 10.1038/nrmicro1709. Nat Rev Microbiol. 2007. PMID: 17558423 Free PMC article. Review.
-
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.J Infect. 2004 Oct;49(3):179-209. doi: 10.1016/j.jinf.2004.05.018. J Infect. 2004. PMID: 15337336 Free PMC article. Review.
-
Peril of the pox. Are primary care providers aware of varicella vaccination guidelines?Can Fam Physician. 2002 Feb;48:316-23. Can Fam Physician. 2002. PMID: 11889891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
